SK4752003A3 - Inhibition of the growth factor dependency of tumor cells - Google Patents

Inhibition of the growth factor dependency of tumor cells Download PDF

Info

Publication number
SK4752003A3
SK4752003A3 SK475-2003A SK4752003A SK4752003A3 SK 4752003 A3 SK4752003 A3 SK 4752003A3 SK 4752003 A SK4752003 A SK 4752003A SK 4752003 A3 SK4752003 A3 SK 4752003A3
Authority
SK
Slovakia
Prior art keywords
use according
carbon atoms
tumor
group
cells
Prior art date
Application number
SK475-2003A
Other languages
English (en)
Slovak (sk)
Inventor
Rosemarie Lichtner
Ulrike Fuhrmann
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10051609A external-priority patent/DE10051609A1/de
Application filed by Schering Ag filed Critical Schering Ag
Publication of SK4752003A3 publication Critical patent/SK4752003A3/sk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK475-2003A 2000-10-18 2001-10-17 Inhibition of the growth factor dependency of tumor cells SK4752003A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24101000P 2000-10-18 2000-10-18
DE10051609A DE10051609A1 (de) 2000-10-18 2000-10-18 Hemmung der Wachstumsfaktorabhängigkeit von Tumorzellen
PCT/EP2001/012004 WO2002032429A2 (en) 2000-10-18 2001-10-17 Use of inhibitors of progesterone receptor for treating cancer

Publications (1)

Publication Number Publication Date
SK4752003A3 true SK4752003A3 (en) 2003-10-07

Family

ID=26007397

Family Applications (1)

Application Number Title Priority Date Filing Date
SK475-2003A SK4752003A3 (en) 2000-10-18 2001-10-17 Inhibition of the growth factor dependency of tumor cells

Country Status (26)

Country Link
EP (1) EP1414465B1 (de)
JP (1) JP4335525B2 (de)
KR (1) KR20030044006A (de)
CN (1) CN1311833C (de)
AT (1) ATE339208T1 (de)
AU (2) AU1595802A (de)
BG (1) BG107745A (de)
BR (1) BR0114677A (de)
CA (1) CA2423013A1 (de)
CY (1) CY1106289T1 (de)
CZ (1) CZ299945B6 (de)
DE (1) DE60123138T2 (de)
DK (1) DK1414465T3 (de)
EA (1) EA005945B1 (de)
EE (1) EE200300156A (de)
ES (1) ES2272561T3 (de)
HK (1) HK1071697A1 (de)
HR (1) HRP20030386A2 (de)
HU (1) HUP0301461A3 (de)
IL (2) IL154974A0 (de)
MX (1) MXPA03002953A (de)
NO (1) NO20031745D0 (de)
NZ (1) NZ545965A (de)
PL (1) PL366415A1 (de)
SK (1) SK4752003A3 (de)
WO (1) WO2002032429A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006054535A1 (de) * 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102010007719A1 (de) * 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0466315A3 (en) * 1990-05-30 1992-07-01 Larrian Gillespie Compositions containing xylan sulphates for affecting growth factor function and for inhibiting fibroblast proliferation
US5238950A (en) * 1991-12-17 1993-08-24 Schering Corporation Inhibitors of platelet-derived growth factor
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
PE20000129A1 (es) * 1997-12-23 2000-03-11 Schering Ag 11 beta-halogeno-estratrienos sustituidos en 7 alfa, asi como el procedimiento para elaborar preparados farmaceuticos que contienen tales 11 beta-halogeno-estratrienos sustituidos en 7 alfa
FR2789393B1 (fr) * 1999-02-05 2001-10-12 Centre Nat Rech Scient Lactol steroidique

Also Published As

Publication number Publication date
NO20031745L (no) 2003-04-15
BG107745A (bg) 2004-01-30
CY1106289T1 (el) 2011-10-12
WO2002032429A3 (en) 2004-02-19
CA2423013A1 (en) 2002-04-25
EP1414465A2 (de) 2004-05-06
BR0114677A (pt) 2003-10-07
IL154974A0 (en) 2003-10-31
CZ299945B6 (cs) 2008-12-29
JP4335525B2 (ja) 2009-09-30
AU2002215958C1 (en) 2002-04-29
CN1311833C (zh) 2007-04-25
HK1071697A1 (en) 2005-07-29
HUP0301461A2 (hu) 2003-10-28
EP1414465B1 (de) 2006-09-13
DK1414465T3 (da) 2007-01-29
ATE339208T1 (de) 2006-10-15
IL154974A (en) 2007-05-15
NO20031745D0 (no) 2003-04-15
WO2002032429A2 (en) 2002-04-25
EA200300468A1 (ru) 2003-10-30
ES2272561T3 (es) 2007-05-01
HUP0301461A3 (en) 2010-01-28
KR20030044006A (ko) 2003-06-02
HRP20030386A2 (en) 2005-04-30
PL366415A1 (en) 2005-01-24
AU2002215958B2 (en) 2006-08-17
AU1595802A (en) 2002-04-29
EE200300156A (et) 2003-08-15
NZ545965A (en) 2007-09-28
JP2004513094A (ja) 2004-04-30
DE60123138T2 (de) 2007-09-13
MXPA03002953A (es) 2003-08-07
DE60123138D1 (de) 2006-10-26
CN1551772A (zh) 2004-12-01
EA005945B1 (ru) 2005-08-25

Similar Documents

Publication Publication Date Title
Labrie et al. EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium
Sherwin et al. Sex steroids and affect in the surgical menopause: a double-blind, cross-over study
Sutherland et al. Effect of medroxyprogesterone acetate on proliferation and cell cycle kinetics of human mammary carcinoma cells
US5362720A (en) Methods of treating or preventing breast or endometrial cancer with low dose non-masculinizing androgenic compounds
HORWITZ The antiprogestin RU38 486: receptor-mediated progestin versus antiprogestin actions screened in estrogen-insensitive T47Dco human breast cancer cells
Strobl et al. Inhibition of human breast cancer cell proliferation in tissue culture by the neuroleptic agents pimozide and thioridazine
US8735381B2 (en) Progesterone antagonists such as CDB-4124 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer, etc
US10201611B2 (en) Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
US9616074B2 (en) Compositions and methods for suppressing endometrial proliferation
SK4752003A3 (en) Inhibition of the growth factor dependency of tumor cells
US20040157811A1 (en) Inhibition of the growth factor dependency of tumor cells
AU2002215958A1 (en) Use of inhibitors of progesterone receptor for treating cancer
HRP20030388A2 (en) Use of antiprogestins for the induction of apoptosis in a cell
UA76128C2 (en) Use of progesterone receptor inhibitors for treating steroid-resistant breast cancer
PT94051B (pt) Processo para a preparacao de composicoes farmaceuticas compreendendo 17alfa-etinil-17beta-hidroxi-18-metil-4,15-estradieno-3-ona-(gestoden)
TW200927137A (en) Compositions and methods for treating dysfunctional uterine bleeding
Köhlerová et al. Biological responses of antiprogestins in mammary gland, uterus and seminal vesicles of prepubertal intact and adult gonadectomized mice
CA2067173A1 (en) Use of antigestagens for the production of pharmaceutical agents

Legal Events

Date Code Title Description
FD9A Suspended procedure due to non-payment of fee